Mesirow Financial Investment Management Equity Management boosted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 19.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,555 shares of the medical equipment provider’s stock after purchasing an additional 6,240 shares during the quarter. Mesirow Financial Investment Management Equity Management’s holdings in Hologic were worth $1,585,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Bank of Montreal Can lifted its stake in Hologic by 37.0% in the third quarter. Bank of Montreal Can now owns 370,187 shares of the medical equipment provider’s stock valued at $15,169,000 after purchasing an additional 99,888 shares during the last quarter. PGGM Investments purchased a new position in Hologic in the third quarter valued at approximately $5,145,000. First Hawaiian Bank purchased a new position in Hologic in the third quarter valued at approximately $397,000. Andra AP fonden lifted its stake in Hologic by 3.1% in the third quarter. Andra AP fonden now owns 92,900 shares of the medical equipment provider’s stock valued at $3,807,000 after purchasing an additional 2,800 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its stake in Hologic by 25.5% in the third quarter. Nisa Investment Advisors LLC now owns 68,426 shares of the medical equipment provider’s stock valued at $2,804,000 after purchasing an additional 13,906 shares during the last quarter. Hedge funds and other institutional investors own 90.43% of the company’s stock.
Several equities analysts recently commented on HOLX shares. Needham & Company LLC reiterated a “buy” rating and issued a $48.00 price objective on shares of Hologic in a research note on Monday, January 14th. Cowen downgraded Hologic from an “outperform” rating to a “market perform” rating and set a $38.28 price objective on the stock. in a research note on Friday, January 4th. Royal Bank of Canada upped their price objective on Hologic from $40.00 to $46.00 and gave the company a “sector perform” rating in a research note on Friday, November 30th. They noted that the move was a valuation call. Zacks Investment Research upgraded Hologic from a “sell” rating to a “hold” rating in a research note on Tuesday, November 13th. Finally, Piper Jaffray Companies dropped their price objective on Hologic to $45.00 and set an “overweight” rating on the stock in a research note on Thursday, November 8th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and seven have issued a buy rating to the company. Hologic currently has an average rating of “Hold” and an average price target of $44.27.
In other Hologic news, insider Peter J. Valenti III sold 4,740 shares of the stock in a transaction on Friday, December 7th. The stock was sold at an average price of $42.20, for a total transaction of $200,028.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Allison P. Bebo sold 6,500 shares of the company’s stock in a transaction on Friday, November 16th. The stock was sold at an average price of $42.00, for a total transaction of $273,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 34,497 shares of company stock worth $1,507,865. Company insiders own 0.90% of the company’s stock.
NASDAQ:HOLX opened at $43.79 on Tuesday. The firm has a market cap of $12.76 billion, a price-to-earnings ratio of 19.64, a P/E/G ratio of 2.05 and a beta of 0.73. Hologic, Inc. has a 1 year low of $35.10 and a 1 year high of $45.45. The company has a current ratio of 1.30, a quick ratio of 0.91 and a debt-to-equity ratio of 1.18.
Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, January 30th. The medical equipment provider reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.01. The firm had revenue of $830.70 million for the quarter, compared to the consensus estimate of $823.22 million. Hologic had a positive return on equity of 25.59% and a negative net margin of 12.88%. The business’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.55 earnings per share. On average, analysts predict that Hologic, Inc. will post 2.41 earnings per share for the current fiscal year.
WARNING: This story was originally posted by Fairfield Current and is the property of of Fairfield Current. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.fairfieldcurrent.com/news/2019/02/12/mesirow-financial-investment-management-equity-management-grows-position-in-hologic-inc-holx.html.
Hologic Company Profile
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Featured Story: How Do Tariffs Affect Trade Balances?
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.